{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:36:50Z","timestamp":1793659010348,"version":"4.5.1"},"reference-count":0,"publisher":"Institute of Hematology, Catholic University","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mediterr J Hematol Infect Dis"],"abstract":"<jats:p>Background:\u00a0Splenic marginal zone lymphoma (SMZL) is a chronic B-cell lymphoproliferative disorder, comprising less than 2% of non-Hodgkin\u2019s lymphomas, and affecting mainly middle-aged and elderly patients with a median survival of &gt;10 years. The typical clinical features of SMZL include splenomegaly. Treatment should be patient-tailored and can range from a \u2018watchful waiting\u2019 approach for asymptomatic patients without cytopenias to surgery, localized radiation therapy or immuno\/chemotherapies. Recently, the combination of Rituximab and Bendamustine (R-Benda) has been defined as highly active in patients with follicular lymphomas, but little is known about the efficacy of R-Benda in SMZL.\u00a0\u00a0Aim of the study: The purpose of this retrospective study was to report our experience on the efficacy of R-Benda as first line treatment in 23 consecutive elderly SMZL patients.\u00a0Results:\u00a0All patients had a complete resolution of splenomegaly along with restoration of their blood counts. Nineteen patients (83%) achieved a complete response (CR) to therapy; three patients (13%) achieved a partial response (PR).Ten patients (43%) obtained molecular remission. Toxicities were mild and mainly haematological and result in dose reductions for fourteen patients.\u00a0Conclusions:\u00a0Our data suggest a high activity and good tolerance of R-Benda, despite dose reduction due to potential toxicity.<\/jats:p>","DOI":"10.4084\/mjhid.2016.030","type":"journal-article","created":{"date-parts":[[2016,6,27]],"date-time":"2016-06-27T05:13:13Z","timestamp":1467004393000},"page":"2016030","source":"Crossref","is-referenced-by-count":7,"title":["BENDAMUSTINE AND RITUXIMAB AS FIRST LINE TREATMENT IN SPLENIC MARGINAL ZONE LYMPHOMAS of ELDERLY PATIENTS."],"prefix":"10.4084","volume":"8","author":[{"given":"Roberto","family":"Castelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2554","published-online":{"date-parts":[[2016,7,1]]},"container-title":["Mediterranean Journal of Hematology and Infectious Diseases"],"original-title":[],"link":[{"URL":"http:\/\/www.mjhid.org\/index.php\/mjhid\/article\/viewFile\/2589\/pdf_89","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.mjhid.org\/index.php\/mjhid\/article\/viewFile\/2589\/pdf_89","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,7,11]],"date-time":"2016-07-11T10:14:08Z","timestamp":1468232048000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.mjhid.org\/index.php\/mjhid\/article\/view\/2016.030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,1]]},"references-count":0,"URL":"https:\/\/doi.org\/10.4084\/mjhid.2016.030","relation":{},"ISSN":["2035-3006"],"issn-type":[{"value":"2035-3006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,1]]}}}